Cargando…

AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)

Antiplatelet and anticoagulant drugs are classified antithrombotic agents with the purpose to reduce blood clot formation. For a successful treatment of many known complex cardiovascular diseases driven by platelet and/or coagulation activity, the need of more than one antithrombotic agent is inevit...

Descripción completa

Detalles Bibliográficos
Autores principales: Winzely, Maximilian, Jouppila, Annukka, Ramer, Georg, Lux, Laurin, Lendl, Bernhard, Barreiro, Karina, Lassila, Riitta, Friedbacher, Gernot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724117/
https://www.ncbi.nlm.nih.gov/pubmed/34773471
http://dx.doi.org/10.1007/s00216-021-03765-y
_version_ 1784625856742686720
author Winzely, Maximilian
Jouppila, Annukka
Ramer, Georg
Lux, Laurin
Lendl, Bernhard
Barreiro, Karina
Lassila, Riitta
Friedbacher, Gernot
author_facet Winzely, Maximilian
Jouppila, Annukka
Ramer, Georg
Lux, Laurin
Lendl, Bernhard
Barreiro, Karina
Lassila, Riitta
Friedbacher, Gernot
author_sort Winzely, Maximilian
collection PubMed
description Antiplatelet and anticoagulant drugs are classified antithrombotic agents with the purpose to reduce blood clot formation. For a successful treatment of many known complex cardiovascular diseases driven by platelet and/or coagulation activity, the need of more than one antithrombotic agent is inevitable. However, combining drugs with different mechanisms of action enhances risk of bleeding. Dual anticoagulant and antiplatelet (APAC), a novel semisynthetic antithrombotic molecule, provides both anticoagulant and antiplatelet properties in preclinical studies. APAC is entering clinical studies with this new exciting approach to manage cardiovascular diseases. For a better understanding of the biological function of APAC, comprehensive knowledge of its structure is essential. In this study, atomic force microscopy (AFM) was used to characterize APAC according to its structure and to investigate the molecular interaction of APAC with von Willebrand factor (VWF), since specific binding of APAC to VWF could reduce platelet accumulation at vascular injury sites. By the optimization of drop-casting experiments, we were able to determine the volume of an individual APAC molecule at around 600 nm(3), and confirm that APAC forms multimers, especially dimers and trimers under the experimental conditions. By studying the drop-casting behavior of APAC and VWF individually, we depictured their interaction by using an indirect approach. Moreover, in vitro and in vivo conducted experiments in pigs supported the AFM results further. Finally, the successful adsorption of APAC to a flat gold surface was confirmed by using photothermal-induced resonance, whereby attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) served as a reference method. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8724117
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-87241172022-01-13 AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan) Winzely, Maximilian Jouppila, Annukka Ramer, Georg Lux, Laurin Lendl, Bernhard Barreiro, Karina Lassila, Riitta Friedbacher, Gernot Anal Bioanal Chem Paper in Forefront Antiplatelet and anticoagulant drugs are classified antithrombotic agents with the purpose to reduce blood clot formation. For a successful treatment of many known complex cardiovascular diseases driven by platelet and/or coagulation activity, the need of more than one antithrombotic agent is inevitable. However, combining drugs with different mechanisms of action enhances risk of bleeding. Dual anticoagulant and antiplatelet (APAC), a novel semisynthetic antithrombotic molecule, provides both anticoagulant and antiplatelet properties in preclinical studies. APAC is entering clinical studies with this new exciting approach to manage cardiovascular diseases. For a better understanding of the biological function of APAC, comprehensive knowledge of its structure is essential. In this study, atomic force microscopy (AFM) was used to characterize APAC according to its structure and to investigate the molecular interaction of APAC with von Willebrand factor (VWF), since specific binding of APAC to VWF could reduce platelet accumulation at vascular injury sites. By the optimization of drop-casting experiments, we were able to determine the volume of an individual APAC molecule at around 600 nm(3), and confirm that APAC forms multimers, especially dimers and trimers under the experimental conditions. By studying the drop-casting behavior of APAC and VWF individually, we depictured their interaction by using an indirect approach. Moreover, in vitro and in vivo conducted experiments in pigs supported the AFM results further. Finally, the successful adsorption of APAC to a flat gold surface was confirmed by using photothermal-induced resonance, whereby attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) served as a reference method. GRAPHICAL ABSTRACT: [Image: see text] Springer Berlin Heidelberg 2021-11-13 2022 /pmc/articles/PMC8724117/ /pubmed/34773471 http://dx.doi.org/10.1007/s00216-021-03765-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Paper in Forefront
Winzely, Maximilian
Jouppila, Annukka
Ramer, Georg
Lux, Laurin
Lendl, Bernhard
Barreiro, Karina
Lassila, Riitta
Friedbacher, Gernot
AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)
title AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)
title_full AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)
title_fullStr AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)
title_full_unstemmed AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)
title_short AFM investigation of APAC (antiplatelet and anticoagulant heparin proteoglycan)
title_sort afm investigation of apac (antiplatelet and anticoagulant heparin proteoglycan)
topic Paper in Forefront
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724117/
https://www.ncbi.nlm.nih.gov/pubmed/34773471
http://dx.doi.org/10.1007/s00216-021-03765-y
work_keys_str_mv AT winzelymaximilian afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan
AT jouppilaannukka afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan
AT ramergeorg afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan
AT luxlaurin afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan
AT lendlbernhard afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan
AT barreirokarina afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan
AT lassilariitta afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan
AT friedbachergernot afminvestigationofapacantiplateletandanticoagulantheparinproteoglycan